Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
Opiate-related Disorders · Opiate Dependence · Drug Abuse
Primary: Subject's Self Assessment Using 10 cm Visual Analogue Scale (VAS) of Overall Preference for One of the Two Buprenorphine-based Maintenance Therapies (Suboxone® or…
Phase 4 N=173 Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
Influenza
Primary: Percentage of Seroprotected Participants Post-vaccination With Fluzone® — 59; 34; 95; 80 Percentage of Participants
Phase 4 N=1,345 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
Meningitis · Meningococcemia · Pertussis
Primary: Percentage of Participants With at Least a 4-fold Rise in Meningococcal Antibody Titer From Baseline (Day 0) to Day 28 Post-vaccination With Menactra® Vaccine. — 92; 94…
Phase 4 N=228 A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
Attention Deficit Hyperactivity Disorder
Primary: Correlation Between Change From Baseline and 24 Week Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent:Investigator-Administered and Scored…
Phase 4 N=93 Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
Acne Vulgaris
Primary: Successful Outcome According to Investigator's Global Assessment (IGA) — 18; 19 participants — p=0.765
Phase 4 N=201 Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia
Asthma
Primary: Change in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With…
Phase 4 N=51 Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
Acne Vulgaris
Primary: Cmax (ng/mL) at Day 1 — 0.10; 0.02 ng/mL
Phase 4 N=100 Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
Nasolabial Folds
Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…
Phase 4 N=315 A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Scores (rTNSS) — -2.45; -3.19 Points on a scale — p=0.004
Phase 4 N=24 Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate
Bacterial Infection
Primary: Maximum Plasma Concentration (Cmax) of Doxycycline — 2.526; 2.442 ug/mL
Phase 4 N=55 Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
Detrusor Hyperreflexia
Primary: Average Catheterization Urine Volume — 95.3; 114.0; 30.0; 52.4 mL
Phase 4 N=92 TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
HIV Infections
Primary: Change From Baseline to Week 12 in Fasting Triglycerides — -0.5; -0.1 mmol/L — p=0.034
Phase 4 N=244 Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
Diabetes · Diabetes Mellitus, Type 2
Primary: Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7% — 64.3; 54.5 percentage of participants — p=0.0411
Phase 4 N=18 Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast) — 7356.3; 9502.1; 6496.0; 1320.7 ng*hr/mL